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Background: Because of the rapid growth in elderly population, polypharmacy has become a serious public health
issue worldwide. Although acute renal failure (ARF) is one negative consequence of polypharmacy, the association
between the duration of polypharmacy and ARF remains unclear. We therefore assessed this association using a
population-based database.
Methods: Data were collected from the Taiwan National Health Insurance Research Database (NHIRD) from 2003
through 2006. The case group included patients hospitalized for ARF during 2006, but not admitted due to trauma,
surgery, burn trauma, car accident, transplantation, or infectious diseases; the control group included patients
hospitalized without ARF. The cumulative number of days of polypharmacy (defined as more than 5 prescriptions
per day) for 1 year prior to admission was determined, with patients further subdivided into 4 categories: less than
30 days, 31–90 days, 91–180 days, and over 181 days. The dependent variable was ARF, and the control variables
were age, gender, comorbidities in patients hospitalized for ARF, stay in ICUs during ARF hospitalization and site of
operation for prior admissions within one month of ARF hospitalization.
Results: Of 20,790 patients who were admitted to hospitals for ARF in 2006, 12,314 (59.23 %) were male and more
than 60 % were older than 65 years. Of patients with and without ARF, 16.14 % and 10.61 %, respectively, received
polypharmacy for 91–180 days and 50.22 % and 24.12 %, respectively, for over 181 days. A statistical model
indicated that, relative to patients who received polypharmacy for less than 30 days, those who received
polypharmacy for 31–90, 91–180 and over 181 days had odds ratios of developing ARF of 1.33 (p<0.001),
1.65 (p<0.001) and 1.74 (p<0.001), respectively.
Conclusions: We observed statistically significant associations between the duration of polypharmacy and the
occurrence of ARF.Background
Polypharmacy has become an emerging public health
issue in recent years. Polypharmacy has been correlated
with adverse drug reactions (ADRs), increased risk of
hospitalization, reduced adherence to medication, and
unnecessary expenses [1,2]. In addition, several studies
have indicated that polypharmacy is directly or indirectly
associated with acute renal failure (ARF) [3-7]. Because
the mortality rate of patients hospitalized for ARF is ap-
proximately 45 %, and almost 30 % of patients with ARF* Correspondence: ihhca@yahoo.com.tw
5Institute of Hospital and Health Care Administration, National Yang Ming
University, 155 Li-Nong St., Sec. 2, Beitou, Taipei 11221, Taiwan
Full list of author information is available at the end of the article
© 2012 Chang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orrequire renal transplantation [8], further assessments of
the association between ARF and polypharmacy would
be important in clinical practice.
Methodological problems are present in studies of the
relationship between polypharmacy and ARF. First, the
definition and measurement of polypharmacy are incon-
sistent [9-13], making comparisons among studies diffi-
cult. For example, polypharmacy has been defined as the
concomitant use of five or more drugs, or as the number
of unnecessary or inappropriate medications [14-16],
with the former definition more widely used by physi-
cians because of its clinical convenience [17]. Second,
most previous studies of the association between poly-
pharmacy and ARF have focused only on elderly people,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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making the results of these studies difficult to compare
across different ages. Third, the involvement of managed
care has resulted in fewer patients with polypharmacy,
because drug benefit plans of managed care programs
vary greatly [17]. Therefore, assessments of the associ-
ation between polypharmacy and ARF require better
health care environments to minimize these interfering
factors.
Our aim of this study is to assess the association be-
tween the duration of polypharnacy and the development
of ARF by analyzing the Taiwan National Health Insur-
ance Research Database (NHIRD). The National Health
Insurance (NHI) of Taiwan, first established in 1995, the
NHI is a nationwide, compulsory, uniform and compre-
hensive health insurance system, in which every citizen
(beneficiary) is covered by the same health benefits, in-
cluding a full drug benefit package, excluded over-the-
counter (OTC) drugs, in western and Chinese traditional
medicine, regardless of the premium paid. Each citizen
has access to any doctor or healthcare institution
throughout the country, with same and low cost-sharing
and/or deductibles. In addition, the NHI has contracts
with over 92 % of all clinics and almost 100 % of all hos-
pitals and other healthcare institutions, which have been
accredited by standards very similar to those of the Joint
Commission International (JCI). The low cost-sharing,
similar quality and high accessibility of medical care have
resulted in an average of 15.1 outpatient visits per person
per year. Each individual receives about 3.35 medications
per prescription, much higher than in European coun-
tries or the United States. These characteristics make
possible a determination of the association between dur-
ation of polypharmacy and ARF [18,19]. In addition, the
NHIRD contains aggregated utilization records on all
individuals throughout the country, including reasons for
utilization in ICD-9-CM diagnostic codes and the medi-
cation details of each enrollee. This information allowed
a determination of the factors influencing ARF, including
gender, age, comorbidities, stay in intensive units (ICUs)
and major site of operation one month prior to ARF ad-
mission, while assessing the association between duration
of polypharmacy and ARF.
Methods
Database and study design
This retrospective case–control study utilized data obtained
from the 2003–2006 NHIRD, which enrolled nearly all 23
million people in Taiwan. The NHIRD, released annually to
the public, contains all claim records, including encrypted
personal identification number, gender, age, five diagnoses
and five treatments(procedure or operation) in ICD-9-CM
(International Classification of Disease, Clinical Modifica-
tion, 9th version) codes, types of lab tests, examinations,medications (in Anatomical Therapeutic Chemical codes),
encrypted health institution code, encrypted physician
identification and all expenditures for inpatient, outpatient,
and emergency department (ED) services. Approval to
analyze NHIRD data was obtained from the Ministry of
Health, Taiwan (No. 1001460109).
The case group was selected from hospitalized patients
diagnosed with ARF (ICD-9-CM: 584) [20-23] for the
first time in 2006, with neither inpatient nor outpatient
histories of ARF within the previous 3 years; none of
these patients had been admitted due to trauma, surgery,
burns, car accident, transplant, or infectious diseases.
The control group was selected from patients hospita-
lized in 2006 but without ARF. None of the control
patients had an inpatient or outpatient history of ARF
within the previous 3 years. Subjects in the control
group were matched 1:4 with those in the case group by
MDC (major diagnosis category), hospital accreditation
level (medical center, regional hospital and community
hospital) and month of hospitalization. The case group
included 20,790 patients and the control group included
83,160 patients (total, 103,950 patients).
Study variables
To investigate the association between the duration of
polypharmacy and ARF, we retrospectively collected
the medication history of all patients for 1 year prior
to hospitalization. The duration of polypharmacy was
defined as the summation of days a patient took more
than 5 prescription medications on a single day in one
year. These patients were further subdivided into those
who took polypharmacy for less than 30, 31–90, 91–
180, and over 181 days. The dependent variable was
the occurrence of ARF (yes/no), whereas the control
variables were those factors which were found by pre-
vious studies to have significant correlation with ARF,
they included age, gender, having comorbidities when
hospitalized for ARF, stay in ICUs during ARF
hospitalization, site of operation for one month prior
to ARF admission and number of days taking NSAID
(Nonsteroidal anti-inflammatory drugs) or Triamterene.
Age was classified into four categories: 0–18, 19–64,
65–79 and over 80 years. A comorbidity was defined
as the diagnosis of and treatment with medication(s),
as inpatient or outpatient for atherosclerotic heart dis-
eases, congestive heart failure, cerebrovascular accident/
transient ischemic attack, peripheral disease, other
cardiac disease, chronic obstructive pulmonary disease,
gastrointestinal bleeding, liver disease, dysrhythmia,
cancer and diabetes; all of these comorbidities have
been highly associated with failures in renal functions
and have been used often in previous studies [24]. Stay
in an ICU was classified as yes or no, depending on
whether a patient had stayed in an ICU during the
Table 1 Descriptive statistics of subjects in case and control groups
Control Group (N = 83,160) Case Group (N = 20,790) Crude odds
ratio
p-value
Number (%) Number (%)
Gender <0.001
Male 44,695 (53.75) 12,314 (59.23) 1.25
Female(ref) 38,465 (46.25) 8,476 (40.77)
Age <0.001
0-18 years old (ref) 15,065 (18.12) 174 (0.84)
19-64 years old 39,199 (47.14) 6,607 (31.78) 14.57
65-79 years old 19,684 (23.67) 8,032 (38.63) 35.28
Over 80 years old 9,212 (11.08) 5,977 (28.75) 56.10
Hospital accreditation status N.A
Medical center 33,544 (40.34) 8,386 (40.34)
Regional hospital 35,240 (42.38) 8,810 (42.38)
Community hospital 14,376 (17.29) 3,594 (17.29)
Duration of polypharmacy <0.001
Less than 30 days(ref) 40,408 (48.59) 4,069 (19.57)
31-90 days 13,867 (16.68) 2,925 (14.07) 2.09
91-180 days 8,823 (10.61) 3,355 (16.14) 3.78
Over 181 days 20,062 (24.12) 10,441 (50.22) 5.17
ICU <0.001
Yes 9,454 (11.37) 9,768 (46.98) 6.91
NSAIDS or Triamterene day* 4.78 (17.23) 8.10 (22.61) 1.01 <0.001
Comorbidity**
ASHD 12,387 (14.90) 5,730 (27.56) 2.17 <0.001
CHF 5,876 (7.07) 4,711 (22.66) 3.85 <0.001
CVA/TIA 9,181 (11.04) 5,289 (25.44) 2.75 <0.001
PVD 2,946 (3.54) 1,578 (7.59) 2.24 <0.001
Other cardiac 5,641 (6.78) 2,538 (12.21) 1.91 <0.001
COPD 14,477 (17.41) 5,605 (26.96) 1.75 <0.001
GI 14,191 (17.06) 6,788 (32.65) 2.36 <0.001
Liver disease 10,338 (12.43) 3,998 (19.23) 1.68 <0.001
Dysrhythmia 5,783 (6.95) 3,952 (14.20) 2.21 <0.001
Cancer 7,718 (9.28) 3,989 (19.19) 2.32 <0.001
Diabetes 16,390 (19.71) 8,396 (40.38) 2.76 <0.001
Site of operation
Nervous system 1,564 (1.88) 285 (1.37) 0.73 <0.001
Endocrine system 1,168 (1.40) 16 (0.08) 0.05 <0.001
Eyes 178 (0.21) 42 (0.20) 0.95 0.736
Ears 79 (0.09) 6 (0.03) 0.30 0.003
Nose, mouth and pharynx 668 (0.80) 67 (0.32) 0.40 <0.001
Respiratory system 4,023 (4.84) 1,902 (9.15) 1.98 <0.001
Cardiovascular system 7,465 (8.89) 5,165 (24.84) 3.35 <0.001
Hemic and lymphatic system 841 (1.01) 265 (1.27) 1.26 0.001
Digestive system 11,578 (13.92) 4,471 (21.51) 1.69 <0.001
Urinary system 8,805 (10.59) 1,286 (6.19) 0.56 <0.001
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Table 1 Descriptive statistics of subjects in case and control groups (Continued)
Male genital organs 71 (0.09) 4 (0.02) 0.23 0.002
Female genital organs 164 (0.20) 1 (0.00) 0.03 <0.001
Obstetrical procedures 0 (0.00) 0 (0.00) - -
Musculoskeletal system 2,933 (3.53) 508 (2.44) 0.69 <0.001
Integumentary system 2,218 (2.67) 626 (3.01) 1.13 0.007
Miscellaneous diagnostic and therapeutic procedures 27,814 (33.45) 12,863 (61.87) 3.23 <0.001
* t test.
**Abbreviations: ASHD, atherosclerotic heart disease; CHF, congestive heart failure;COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular
accident/transient ischemic attack; GI, gastrointestinal bleeding; PVD, peripheral vascular disease.
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found in previous studies as a factor correlated to ARF
hospitalization [25]. In our study, site of operation was
defined as having a primary operation (in ICD-9-CM OP
codes) on the nervous system, endocrine system, eyes,
ears, nose, mouth and pharynx, respiratory system, car-
diovascular system, hemic and lymphatic system, digestive
system, urinary system, male genital organs, female
genital organs, musculoskeletal system, or integumentary
system, or as obstetric or miscellaneous diagnostic and
therapeutic procedures one month prior to ARF
hospitalization. NSAID or Triamterene drugs were also
found to be correlated to renal failure [26,27]. Therefore,
we also included number of days taking both classes of
drugs as a control variable.
Statistical analysis
Data were analyzed using SAS version 9.2 (SAS Institute
Inc., Cary, NC, USA). In the analysis of single dependent
variables, we first used descriptive statistics to determine
the distribution of age, gender, comorbidities, ICU and
site of operation in patients with and without ARF and
in patients with cumulative use of polypharmacy for less
than 30, 31–90, 91–180, and over 181 days. χ2 and t
tests were used to assess the association between the
duration of polypharmacy and the occurrence of ARF
and to investigate the variables that significantly affected
ARF. Stepwise logistic regression analysis was utilized to
determine the association between ARF and the duration
of polypharmacy after controlling for patient variables.
Results
The demographic and clinical characteristics of the case
and control groups are shown in Table 1. We found
that ARF was significantly correlated with male gender
(p<0.001), with 59.23 % of patients with ARF being
male. ARF also increased with age; of ARF patients,
0.84 % were aged 0–18 years, 31.78 % were aged 19–
64 years, 38.63 % were aged 65–79 years and 28.75 %
were over 80 years old. When the study samples were
paired with hospital accreditation status, the results of
χ2 tests were not significant. When we assessed theassociation between ARF and duration of polypharmacy,
we found that a higher proportion of case than control
patients received polypharmacy for 91–180 (16.14 % vs.
10.61 %) and for over 181 days (50.22 % vs. 24.12 %).
Statistical analyses showed that all comorbidities tested
were significantly correlated with ARF (p<0.001), with
all odds ratios being >1.00. A higher percentage of
patients in the case group stayed in the ICU during
hospitalization (46.98 % vs. 11.37 %). Site of operation
was significantly correlated with ARF (p<0.001), except
for operations on the ears (p<0.736). The case group had
significantly longer days in taking NSAID or Triamter-
ene drugs than the control group (8.10 ± 22.61 days vs.
4.78 ± 17.23 days, p<0.001).
Table 2 shows the results of a stepwise logistic re-
gression analysis, in which ARF was the dependent
variable, polypharmacy duration was the independent
variable, and the influence of gender, age, ICU, comor-
bidities and site of operation were controlled. Com-
pared with cases who received polypharmacy for less
than 30 days, all other polypharmacy categories were
at higher risks for ARF (p<0.001), with the odds ratios
(OR) increasing with increasing duration of polyphar-
macy, being 1.33, 1.65 and 1.74, in patients who
received polypharmacy for 31–90, 91–180, and over
181 days, respectively. Males were 1.32 (p<0.001) times
more likely than females to develop ARF and increased
age was also associated with ARF. Relative to patients
aged 0–18 years old, those aged 19–65, 65–79, and
over 80 years had ORs for the development of ARF of
6.40, 8.93 and 14.46, respectively. Stay in the ICU was
also significantly associated with the development of
ARF (OR 4.37; p<0.001).
All comorbidities, except for atherosclerotic heart dis-
ease, dysarrhythmia and chronic obstructive pulmonary
disease, were associated with higher risks of ARF (OR
>1.00 each; p<0.001). Only surgical operations on the
cardiovascular system, digestive system, integumentary
system and miscellaneous diagnostic and therapeutic
procedures showed ORs >1.00 and with statistical signifi-
cant (p<0.05 each). In contrast, operations on the ner-
vous system, endocrine system, nose, mouth and





Duration of polypharmacy: Less than 30 days*
31- 90 days 0.28 0.03 1.33 <0.001
91 – 180 days 0.50 0.03 1.65 <0.001
Over 181 days 0.55 0.03 1.74 <0.001
Gender:Female*
Male 0.28 0.02 1.32 <0.001
Age:0-18 years old *
19-64 years old 1.86 0.08 6.40 <0.001
65-79 years old 2.19 0.08 8.93 <0.001
Over 80 years old 2.67 0.08 14.46 <0.001
ICUs 1.48 0.02 4.37 <0.001
Comorbidity
ASHD −0.23 0.02 0.80 <0.001
CHF 0.67 0.03 1.95 <0.001
CVA/TIA 0.21 0.02 1.24 <0.001
PVD 0.14 0.04 1.15 0.001
Other cardiac 0.08 0.03 1.09 0.006
COPD −0.10 0.02 0.91 <0.001
GI 0.30 0.02 1.36 <0.001
Liver disease 0.15 0.02 1.16 <0.001
Cancer 0.65 0.02 1.92 <0.001
Diabetes 0.46 0.02 1.58 <0.001
Site of operation
Nervous system −0.82 0.07 0.44 <0.001
Endocrine system −2.25 0.26 0.11 <0.001
Nose, mouth and pharynx −0.58 0.14 0.56 <0.001
Respiratory system −0.30 0.03 0.75 <0.001
Cardiovascular system 0.38 0.02 1.47 <0.001
Digestive system 0.26 0.02 1.30 <0.001
Urinary system −0.21 0.03 0.81 <0.001
Male genital organs −1.38 0.54 0.25 0.010
Female genital organs −2.63 1.01 0.07 0.009
Musculoskeletal system −0.15 0.06 0.86 0.007
Integumentary system 0.11 0.05 1.12 0.039
Miscellaneous diagnostic
and therapeutic procedures
0.35 0.02 1.42 <0.001
* reference group.
Chang et al. BMC Nephrology 2012, 13:96 Page 5 of 7
http://www.biomedcentral.com/1471-2369/13/96pharynx, respiratory system, urinary system, male genital
organs, female genital organs and musculoskeletal system
had a negative coefficient (between −2.63 and −0.15)
compared with other sites of operation. Number of
NSAID or Triamterene days was not selected to be
included in the stepwise logistic regression model.Discussion
Our analysis of a dataset from the population-based
NHIRD revealed a positive association between the dur-
ation of polypharmacy and the occurrence of ARF. Even
after controlling for other factors, a longer duration of
polypharmacy was associated with a higher risk of ARF.
The adoption of managed care systems by more coun-
tries has made research focusing on polypharmacy
[17,28], especially duration of polypharmacy, more diffi-
cult to perform. Usually the medications prescribed to
enrollees in managed care programs are highly con-
trolled, whereas non-prescription medications are not.
The lack of information about non-prescription medica-
tions makes it very difficult to trace polypharmacy under
managed care environments. The actual occurrence of
polypharmacy may be higher than that reported, since
many people do not inform their doctors about taking
non-prescription drugs regularly. This situation, however,
is rare in Taiwan, because the NHI pays for most drugs
for acute and chronic diseases, and enrollees seldom
spend their own money to buy nonprescription drugs
regularly. It has made it easier to assess polypharmacy in
Taiwan than in other countries. Moreover, since we
defined polypharmacy as the concomitant use of more
than five medications and we assessed the cumulative
days of polypharmacy, we were better able to assess the
duration of polypharmacy and the association of duration
with ARF (or adverse drug events leading to ARF) than
previous studies, which assessed only the correlation be-
tween polypharmacy and ARF [1,2,4,7,10,29-31]. Indeed,
we found that patients with a longer duration of poly-
pharmacy were at higher risk for ARF hospitalization,
consistent with previous findings reporting that excessive
medication intake can cause renal damage and ARF
[32-34]. Although we did not observe any significant dif-
ferences between our case and control groups in the rea-
sons for medication, we found that the average duration
of polypharmacy was longer in the case than in the con-
trol group (191 days vs. 146 days). Therefore, the main
cause of ARF may not be the medication itself, but rather
the cumulative effects of polypharmacy. After controlling
for confounding factors, including comorbidities, stay in
the ICU during ARF hospitalization or site of operation
within one month prior to ARF hospitalization, we still
found that the risk of ARF was associated with duration
of polypharmacy.
Consistent with previous reports, we found that poly-
pharmacy was more likely to occur in elderly people
[3,9,12]. The cumulative duration of polypharmacy in
elderly people was likely higher because many of these
individuals may take more than 5 medications per day
due to multiple chronic diseases, including gastrointes-
tinal bleeding, diabetes, chronic obstructive pulmonary
disease and atherosclerotic heart disease. The optimal
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courage doctors to avoid prescribing multiple medica-
tions or medications with renal toxicity to elderly
people, or to prescribe medications at minimal doses
[35]. This, however, may become more unrealistic since
the elderly population in many countries is growing rap-
idly. Therefore, more research is necessary to reduce in-
appropriate medications in elderly patients requiring
long duration of polypharmacy.
We also found that comorbidities, ICU stay during
hospitalization for ARF and site of operation within one
month prior to ARF hospitalization were associated with
higher risks of ARF, findings consistent with previous
reports [36,37]. Our finding, however, that dysrhythmia
was not associated with a risk of ARF, differed from those
showing associations between cardiac diseases and ARF
[38-40]. Our result may have been because of the inclu-
sion of too many cardiac comorbidities in our logistic re-
gression analysis. Although the number of days taking
NSAID or Triamterene drugs was found significantly dif-
ferent between two groups, it was not selected in step-
wise logistic regression model. It was probably because
the number of days taking NSAID or triamterene drug
was highly correlated with the duration of polyphamacy.
This study had two main limitations. First, we relied
on medication claims in the NHIRD database to define
polypharmacy. In reality, some patients may have pur-
chased or taken medications on their own, thus under-
estimating the actual occurrence and duration of
polypharmacy. However, due to the high accessibility of
Taiwan’s universal health insurance and the wide cover-
age for medications, few people would purchase medica-
tions on their own. Therefore, the influence of this
underestimation on our results were likely minimal. Sec-
ond, this study was limited by the use of this database,
in that our case group included patients without a his-
tory of ARF for the previous three years, minimizing the
effects of previous ARF on current ARF.
Conclusions
We observed statistically significant associations be-
tween the duration of polypharmacy and the occurrence
of ARF in this study. However, this association needs
further study to ensure a causal relationship. In addition,
the study of duration of polypharmacy also needs further
attentions to specific group of people, such as elderly
patients with multiple chronic diseases, since the society
of many developed countries age very soon.
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